About KAYA17: Making a Critical Difference

KAYA17 was established in 2015 with the primary objective of reducing the time between testing, diagnosis and treatment, thus seeking to fundamentally improve efficiencies in healthcare.


A Mission to Enable On-site Diagnostic Testing

Building upon our success in identifying food pathogens in produce (fruits and vegetables), we have updated the design of the various components to be able to identify bacteria, virus, pollen and other protein-based pathogens in small specimen samples with very high sensitivity.

Currently, we have developed a solution for the quick and timely diagnosis of the SARS-CoV-2 virus, which has caused the largest pandemic in recent history.

Looking to the future, we are developing rapid anti-body tests for COVID-19 which can evaluate immunity levels in person’s who have received a vaccination. As at present, there is no reliable data to indicate how long immunity from a vaccine will last. Only periodic anti-body testing, over a period of 2-3 years will provide accurate, actionable data. Additionally, rapid tests for other medical conditions such as tests for allergens, certain cancers, infectious diseases such as dengue fever, and other mutations of the SARS virus, will be created by KAYA17. Some basic research for these tests has already been completed.


Our Team

Sulatha Dwarakanath, PhD

CEO / Co-Founder

Su has a PhD in Molecular Biology from New York University. She has over 20 years of experience in Product Innovation, Development and Strategy at Roche Diagnostics, Thermo Fisher Scientific, and Bayer Diagnostics. She was the Founder and Chief Scientific Officer of Nano Science Diagnostics, a Point of Care focused company.

Srinagesh Satyanarayana, PhD

CTO / Co-Founder

Sri has a PhD in Electrical Engineering from Columbia University. He has more than 25 years of experience in Analog chip design electronic systems, medical devices, and Artificial Intelligence based systems. He was the Founder and CEO of Free Electron Technology, a 10 Gbps Communications Chip company.

Camille Troup, PhD

Chief Scientific Officer

Camille received her PhD in Molecular Biology from University of California at San Francisco. She has over 25 years of experience developing and commercializing biomolecular assays and platforms.

Anup Madan

Chief Operations Officer

Anup brings more than 20 years of experience in delivering innovative solutions to support multiple aspects of clinical trials.

Rajan Pillai

VP of Business Development

Rajan co-founded Duramed Pharmaceuticals which went public, Trinity Laboratories, which was acquired, and a mail order prescription drug company, Medi Rx America, which went public. He has worked as Managing Director at Peregrine Capital Ltd. in Hong Kong for four years during 1993-1997. During his years as a practicing attorney in New York, he has represented the Governments of Indonesia and Sweden in certain commercial matters, and has handled several IPOs of successful early stage enterprises.

Steve Verbinski, MD

Chief Medical Officer

Dr. Verbinski received his Bachelors from Stanford university, M.D from Duke University Medical School, and he did his residency from UCSF. He has served as Nocturnist/Hospitalist at San Mateo General Hospital, In Internal medicine at U.S. Health Service Corps at Yuba City/Marysville/Olivehurst. He was a hospitalist at Eden Medical Center, Castro Valley CA, and is currently Full time Hospitalist and Co-director at St. Rose Hospital Hayward, CA. He has served as chair of several Medical committees at St. Rose Hospital. He received the “Rose Award” for Most Outstanding Service at St. Rose Hospital twice. Aside from his job he volunteers at Livermore Valley School district as medical advisor for Opiod overdose. He is also Physician advisor to the COVID Response Task Force/Command Center St. Rose Hospital.

Shreefal Mehta Ph.D., MBA

Chief Commercialization Officer

Shreefal is a serial entrepreneur, who has successfully 
brought new technologies from lab prototypes to market 
in biotechnology and electronics hardware 
(new type of battery). He has raised millions of dollars
from venture capital for his previous ventures, 
forged strategic partnerships with Fortune 500 companies 
and driven over $350M in licensing and sales revenues.












Advisory Panel

George H. Caughey, MD

Chief of Pulmonary and Critical Care Medicine, Julius and Lilian Nadel Endowed Chair, UCSF; Professor Emeritus, Medicine, UCSF

Nancy B. Mozelsio, MD

Clinical Practice, Allergy & Asthma Medical Group of Bay Area, Pleasanton & Walnut Creek

Yolanda Fintschenko

FounderTraction; Digital Marketing for Tech and Biotech

Mitchell Levinson

Medical Device Developer & Entrepreneur Experienced medical device developer and entrepreneur with over 30 years in the industry. In 2010, Mr. Levinson co-founded Cerebrotech Medical Systems, Inc.. Previously CEO of Zeltiq Aesthetics, Inc. (Coolsculpting, ZLTQ) and VP of Thermage, Inc. (later renamed Solta Medical, SLTA). Levinson also sits on the Board of Directors of Pulse Biosciences (PLSE) and ConnectWell.

Allyson Tevrizian, MD

Clinical Practice, Allergy and Asthma Medical Group of Bay Area, Pleasanton

Peter Andreotti

Dr. Andreotti has over 25 years of experience developing immunoassays including more than 10 years of contractor experience (2002-2012) developing TRF and CLIA assays for special pathogens and toxins as a DARPA PI and PI for DHS and the CDC/LRN. Dr. Andreotti was also a PM for the AF/SGR to develop a multiplex rt-PCR platform for the Epidemic Outbreak Surveillance (EOS) program in collaboration with CDC.